FGFR2 and neoplasm: More recently, Amgen has developed and commenced clinical testing of bemarituzumab (FPA144), a humanized IgG1 monoclonal antibody targeting FGFR2-IIIb, which has also been glycoengineered (afucosylated) to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) against FGFR2-IIIb-expressing tumour cells.